Different systems. Useful questions. | A question to investigate
340B | Make the boundary visible before making the business case
A 340B-related proposal should become more precise as it becomes more attractive. Which covered entity, which activity, which records and which accountable process are actually in scope? Our interest is in helping an authorised organisation prepare a clearer operational question, while recognising that a financial narrative cannot stand in for programme requirements or specialist interpretation of a particular arrangement.
In the conversation.
NEUVIOR and our founder’s perspectives have appeared across science, business and technology publications.
Reporting, commentary, letters and podcast appearances | Read each feature for its format and source.
Begin with the covered entity’s authority
A pharmacy director, programme lead or finance sponsor within an eligible organisation may wish to understand a defined operational process. A contract pharmacy may have a different role and authority. We would establish the accountable organisation and permitted work before discussing data. The incentive is a clearer review and a more inspectable decision, not a promise to establish eligibility, increase purchases or maximise a programme benefit through software.
Keep official requirements in view
HRSA describes registration, annual recertification, prevention of diversion and duplicate discounts, and auditable records among programme requirements (HRSA, n.d.). Those principles provide context; this page is not a determination of compliance. A proposed review would identify where local specialist judgement is needed and would never turn a neat reconciliation into a declaration that every underlying transaction is eligible. The responsible organisation retains its programme obligations.
Choose one operational question
An initial discussion could concern how an organisation prepares an internal exception review or reconciles authorised aggregate reports. The sponsor would define a single workflow, the source systems involved and the decision that follows. Inputs would be limited to records that can be used for the agreed purpose. We would prefer a historical, controlled sample before considering any connection to a live operational process.
A comparator that preserves accountability
The existing review method would be the comparator, using the same sample and written question. We would measure preparation effort, unresolved mismatches, source traceability and whether a qualified local reviewer can challenge each conclusion. An independently checked set of examples could test the classification process. The study would assess the usefulness of decision preparation, not certify transactions or claim to replace an audit.
A public decision brief | An illustrative example
Open the question.
Inspect the reasoning.
Choose a business question, then look beneath its claim. See what a public source supports, what depends on the local setting and what a useful next step could be.
A US-facing medicines business, analyst or research team deciding whether a public spending comparison is meaningful.
The same medicine. A different denominator.
A spending figure becomes useful when the reader knows the programme, period, unit and exclusions behind it. Reconciliation comes before an attractive price comparison.
A proposition to investigate
A comparable question before a bigger chart.
A public-data brief could identify whether two measures describe sufficiently similar activity to compare. The proposed value is a traceable inclusion decision and a clear definition of the measure. No current price, negotiated saving, purchasing recommendation or live dataset calculation is produced in this specimen.
The reconciliation task is constructed. No records have been joined or analysed in this example.
What the next brief would contain
A decision someone
can commission.
- The decision
- Whether a defined public-data comparison is valid enough to commission.
- The comparator
- A second explicitly defined source with comparable scope, units and period.
- The evidence
- Source editions, medicine mapping, population, units, exclusions and reproducible inclusion rules.
- Stop or redesign
- Exclude comparisons when the denominator or cost meaning cannot be reconciled; retain the exclusion reason.
Constructed public example | Not PHARMORIS-generated software output or a measured customer result.
Keep this example briefDo not invent a net financial benefit
A financial scenario would need clearly identified purchase, payment and operating-cost assumptions. An observed mismatch is not automatically an overpayment, an eligible discount or a recoverable amount. We would distinguish gross figures from net effects and exclude unsupported commercial terms. The programme’s purpose and the organisation’s responsibilities should remain visible rather than reducing the evaluation to the largest possible financial headline.
Current interpretation needs current review
HRSA’s programme resources and notices are the starting point for current official context (HRSA, n.d.). Specific arrangements may involve additional facts and specialist advice. We would date the sources used and stop a review if the question depends on unresolved legal or policy interpretation beyond the agreed scope. A historical pilot would not be described as assurance that future transactions, contract arrangements or policy changes are covered.
The threshold for continuing
Continuation would require an authorised sponsor, usable records and a verified improvement in the defined review process. We would stop if the study cannot separate data errors from programme judgements or if the necessary expertise is unavailable. A commercially useful result may be a clearer set of questions for the organisation’s existing advisers. That is a bounded value proposition; it does not imply that NEUVIOR has been appointed as a 340B auditor or programme administrator.
Sources and reading context
Official source context checked on 13 October 2026. The study design above is a NEUVIOR proposal for discussion, not a reported deployment or result.
HRSA | 340B Program Requirements
HRSA | 340B Drug Pricing Program
HRSA (n.d.) 340B Program Requirements. Available at: https://www.hrsa.gov/opa/program-requirements (Accessed: 14 October 2026).
HRSA (n.d.) 340B Drug Pricing Program. Available at: https://www.hrsa.gov/opa (Accessed: 14 October 2026).
Discuss a bounded 340B review question
Bring the decision you need to make, the person accountable for it and the evidence you can use. We can then discuss whether a bounded PHARMORIS evaluation is the right next step.
Another useful angle.
- US health plans | Make the medicines case explicit
Explore a proposed PHARMORIS evidence-preparation study for US health plans, separating benefit design, operational effort and accountable decision-making.
- US health-system pharmacy | Make the next operational choice defensible
Explore a bounded PHARMORIS study for US health-system pharmacy leaders evaluating a medicines workflow with operational and financial comparators.
- US formulary review | A clearer argument deserves a clearer challenge
A proposed PHARMORIS evidence-preparation study for US formulary and medicines committees, with traceability, comparator and implementation checks.